Overview

* Tonix Q2 reports net loss of $28.3 mln, compared to net loss of $78.8 million last year

* Reports basic EPS of -$3.86

* Company's cash position improves to $125.3 mln, funding operations into Q3 2026

Outlook

* Tonix expects FDA decision on TNX-102 SL by August 15, 2025

* Company anticipates cash runway to fund operations into Q3 2026

* Tonix preparing for potential TNX-102 SL commercialization in Q4 2025

Result Drivers

* TNX-102 SL - Phase 3 results show significant pain reduction in fibromyalgia patients, supporting NDA review

* INCREASED EXPENSES - Higher SG&A expenses due to pre-launch activities for TNX-102 SL

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$28.27

Income mln

Q2 Basic -$3.86 -$3.21

EPS (2

Analysts

)

Q2 -$28.30 -$26.30

Operatin mln mln (1

g Income Analyst)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp ( TNXP ) is $65.00, about 28.5% above its August 8 closing price of $46.49

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)